Black Diamond Therapeutics Inc (NASDAQ: BDTX) kicked off on Friday, down -4.47% from the previous trading day, before settling in for the closing price of $2.46. Over the past 52 weeks, BDTX has traded in a range of $1.20-$6.75.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -5.22%. While this was happening, its average annual earnings per share was recorded 119.16%. With a float of $43.28 million, this company’s outstanding shares have now reached $56.68 million.
Let’s determine the extent of company efficiency that accounts for 24 employees. In terms of profitability, gross margin is 99.75%, operating margin of -5.72%, and the pretax margin is 7.27%.
Black Diamond Therapeutics Inc (BDTX) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Black Diamond Therapeutics Inc is 23.88%, while institutional ownership is 62.07%. The most recent insider transaction that took place on Mar 19 ’25, was worth 11,997,749. In this transaction 10% Owner of this company sold 5,784,292 shares at a rate of $2.07, taking the stock ownership to the 2,733,547 shares. Before that another transaction happened on Aug 28 ’24, when Company’s 10% Owner sold 221,600 for $6.32, making the entire transaction worth $1,400,556. This insider now owns 3,726,341 shares in total.
Black Diamond Therapeutics Inc (BDTX) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 119.16% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 2.33% during the next five years compared to -5.22% drop over the previous five years of trading.
Black Diamond Therapeutics Inc (NASDAQ: BDTX) Trading Performance Indicators
Take a look at Black Diamond Therapeutics Inc’s (BDTX) current performance indicators. Last quarter, stock had a quick ratio of 9.24. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.91.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.06, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -1.02 in one year’s time.
Technical Analysis of Black Diamond Therapeutics Inc (BDTX)
Looking closely at Black Diamond Therapeutics Inc (NASDAQ: BDTX), its last 5-days average volume was 2.11 million, which is a drop from its year-to-date volume of 2.29 million. As of the previous 9 days, the stock’s Stochastic %D was 56.55%.
During the past 100 days, Black Diamond Therapeutics Inc’s (BDTX) raw stochastic average was set at 72.78%, which indicates a significant increase from 35.71% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 64.45% in the past 14 days, which was lower than the 79.32% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.03, while its 200-day Moving Average is $2.51. However, in the short run, Black Diamond Therapeutics Inc’s stock first resistance to watch stands at $2.49. Second resistance stands at $2.62. The third major resistance level sits at $2.70. If the price goes on to break the first support level at $2.28, it is likely to go to the next support level at $2.20. Now, if the price goes above the second support level, the third support stands at $2.07.
Black Diamond Therapeutics Inc (NASDAQ: BDTX) Key Stats
The company with the Market Capitalisation of 133.63 million has total of 56,863K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -69,680 K annual income. Company’s last quarter sales were recorded 70,000 K and last quarter income was 56,540 K.
